KE

AI Memo

Kimball Electronics

As of 2026-10-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Fiscal Q1 2027 results on November 4 • 2026-11-04

Base target: $27 / p=50% prob

Biggest risk

Fiscal 2026 Q4 automotive and industrial sales fell 3% and 5% year over year, respectively. Program start-ups can dilute margins, and customer orders may arrive only shortly before production; the growth plan could therefore disappoint despite acquisition revenue. [#SEC-8K-2026-08-12] [#SEC-10K-2026-08-19] (SEC earnings exhibit, SEC 10-K)

Invalidation

Break below $19 or thesis failure.

What would change my mind?

Fiscal 2026 Q4 sales rose 5% sequentially and operating cash flow was $42.4 million. If fiscal 2027 organic growth and Helvoet’s contribution arrive without material margin dilution, the recovery thesis strengthens. [#SEC-8K-2026-08-12] (SEC earnings exhibit)

Research note

Recommendation

—

Confidence

medium

As of

2026-10-25

Base target

$27

p=50%

Bull target

$32

p=25%

Bear target

$19

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Fiscal 2027 organic growth and Helvoet contribution
Medical expansion versus margin and capital demands
Fiscal 2026 Q4 sales rose 5% sequentially and operating cash flow was $42.4 million.

BearKey bullets

Component shortages, shipping delays and short-order visibility could impair delivery or working capital.
[#SEC-10K-2026-08-19] (SEC 10-K)
Fiscal 2027 guidance calls for $50–$60 million of capital expenditures, making cash conversion worth monitoring alongside sales growth.

WatchKey bullets

Fiscal Q1 2027 results on November 4

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $27 (p=50%)

Target spread vs base: +19% / -30%

Scenario probabilities

Bull Target: $32 (p=25%)Base Target: $27 (p=50%)Bear Target: $19 (p=25%)

Commentary

The recent company announcement supplies a dated Q1 reporting event, but not new operating results. The packet does not verify a 30-day news-tone measure, social coverage, options skew, short interest, employee score, post-August earnings price reaction or analyst revisions; zero sentiment fields mean unavailable, not neutral. The positive structured prior is moderated by low coverage and the need to validate fiscal 2027 execution. [#PR-EARNINGS-2026-10-21] [#SEC-8K-2026-08-12]

As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Fiscal 2027 organic growth and Helvoet contribution
Medical expansion versus margin and capital demands

Scenarios

Bull Target (Scenario probability)

$32 / p=25% prob

Base Target (Scenario probability)

$27 / p=50% prob

Bear Target (Scenario probability)

$19 / p=25% prob

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-04
Fiscal Q1 2027 results on November 4
Kimball plans to report after the market closes on November 4, with a call on November 5. The decision-relevant test is whether early organic growth and Helvoet sales support fiscal 2027 guidance; no Q1 result is available yet. [#PR-EARNINGS-2026-10-21] [#SEC-8K-2026-08-12]
Prob 100.00% • Move 7.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Fiscal 2027 organic growth and Helvoet contribution
2027-06-30
The August earnings exhibit guides to $1.535–$1.560 billion of fiscal 2027 sales, including 3%–5% organic growth and approximately $60 million from Helvoet. Delivery would distinguish an underlying recovery from acquisition-led growth. [#8-K-2026-08-12] [#SEC-8K-2026-08-12] (SEC earnings exhibit)
Prob 60% • Move 14% • Priced-in 45%
Medical expansion versus margin and capital demands
2027-06-30
Management expects Medical to exceed one-third of fiscal 2027 sales, while guiding to a 4.4%–4.7% adjusted operating margin and $50–$60 million of capital expenditures. The test is whether medical growth and the Indianapolis and Helvoet investments translate into durable earnings and cash flow. [#SEC-8K-2026-08-12] [#SEC-10K-2026-08-19] (SEC earnings exhibit, SEC 10-K)
Prob 55% • Move 10% • Priced-in 35%

Risks

Component shortages, shipping delays and short-order visibility could impair delivery or working capital. [#SEC-10K-2026-08-19] (SEC 10-K)
Fiscal 2027 guidance calls for $50–$60 million of capital expenditures, making cash conversion worth monitoring alongside sales growth. [#SEC-8K-2026-08-12] (SEC earnings exhibit)
Medical facility ramp and Helvoet integration could raise start-up costs or delay margin improvement. [#SEC-10K-2026-08-19] (SEC 10-K)
The 10-K reports fiscal 2026 sales concentration of 18% at Nexteer, 11% at Philips and 11% at ZF; these are customer exposures, not evidence of a current demand change. [#SEC-10K-2026-08-19] (SEC 10-K)

Peers

Symbol	Summary
BHE	Benchmark Electronics is a direct EMS competitor named in Kimball’s 2026 10-K, although customer and program mix limit valuation read-through. [#SEC-10K-2026-08-19] (SEC 10-K)
PLXS	Plexus is another EMS competitor named in the 10-K; its scale and end-market mix are not identical to Kimball’s. [#SEC-10K-2026-08-19] (SEC 10-K)

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-25

Loading AI feed…

Symbol

Summary

BHE

Benchmark Electronics is a direct EMS competitor named in Kimball’s 2026 10-K, although customer and program mix limit valuation read-through. [#SEC-10K-2026-08-19] (SEC 10-K)

PLXS

Plexus is another EMS competitor named in the 10-K; its scale and end-market mix are not identical to Kimball’s. [#SEC-10K-2026-08-19] (SEC 10-K)